Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Folarin OS, Siddiqui MT. Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria. Cancer Cytopathol. 2023;131(11):708-715.

Marx CE, Schenker C, Xu Y, Salvatore SP, Kahn SR, Garcia D, et al. Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort. J Thromb Haemost. 2023;21(10):2908-2912.

Elhadad S, Redmond D, Tan A, Huang J, Rodriguez BL, Racine-Brzostek SE, et al. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023;225:47-56.

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.

Magro CM, Kalomeris T, Roberts A. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal. Ann Diagn Pathol. 2023;63:152101.

Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141(8):904-916.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, et al. Novel genetically engineered mouse models for clear cell renal cell carcinoma. Sci Rep. 2023;13(1):8246.

Imada EL, Wilks C, Langmead B, Marchionni L. REPAC: analysis of alternative polyadenylation from RNA-sequencing data. Genome Biol. 2023;24(1):22.

Karaaslan S, Dilcher TL, Abdelsayed M, Goyal A. Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests. J Am Soc Cytopathol. 2023;12(3):189-196.

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.